Page last updated: 2024-10-21

n-methyl-3,4-methylenedioxyamphetamine and Fatty Liver

n-methyl-3,4-methylenedioxyamphetamine has been researched along with Fatty Liver in 1 studies

N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.

Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Research Excerpts

ExcerptRelevanceReference
" Pathohistology revealed microvascular steatosis in the liver, which raised the possibility of chronic use of toxic substances."1.38[A new designer drug: methylone related death]. ( Kereszty, EM; Kovács, K; Tóth, AR, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kovács, K1
Tóth, AR1
Kereszty, EM1

Other Studies

1 other study available for n-methyl-3,4-methylenedioxyamphetamine and Fatty Liver

ArticleYear
[A new designer drug: methylone related death].
    Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7

    Topics: Adolescent; Amphetamine; Asthma; Autopsy; Causality; Death, Sudden, Cardiac; Designer Drugs; Drug Ov

2012